Partnership redefines local manufacturing of biologics

Pharma News: A strategic partnership to provide integrated drug substance and drug product solutions for biologics developers has been announced between BioCina, an Australian end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina, a fill-and-finish CDMO.

BioCina, known for its services encompassing cell line development, process development, and cGMP drug substance manufacturing for microbial, pDNA, and mRNA modalities, is set to enhance its offerings by incorporating NovaCina’s expertise in clinical and commercial fill-and-finish services. This collaboration allows BioCina to deliver fill-and-finish solutions to its clients, transforming drug substances produced at its cutting-edge facility in Adelaide, South Australia, into ready-to-use drug products at NovaCina’s advanced facility in Perth, Australia.

Mark Womack, CEO of BioCina and member of NovaCina’s Board of Directors, expressed his enthusiasm for the partnership, saying “BioCina is excited to partner with NovaCina, integrating our globally recognised expertise in clinical and commercial process development and drug substance manufacturing with their esteemed drug product services. This partnership promises to deliver unparalleled quality, adherence to the highest regulatory standards, and on-time delivery of client programs, setting a new benchmark in the market.”

Cyrus Mirsaidi, CEO of NovaCina, echoed the sentiment, stating “We are very excited to form this partnership with BioCina. Together, we provide a seamless end-to-end offering. At NovaCina, we are delighted to bring our world-class quality and safety to this value-adding collaboration.”

This alliance marks a significant milestone in the biopharmaceutical manufacturing landscape, promising clients worldwide access to end-to-end solutions of the highest quality. Clients of BioCina will now benefit from NovaCina’s decades of clinical and commercial fill-and-finish experience, supported by multiple regulatory approvals, including those from the U.S. Food and Drug Administration (FDA). NovaCina’s comprehensive suite of services includes development, manufacturing, packaging, labelling, and stability studies.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.